87% of Midlife Women Don't Get Menopause Care: Mayo Study
5/11/2026
5 min read
By The TRT Catalog
New Mayo Clinic Proceedings study of ~5,000 women: 87% didn't seek care for menopause symptoms despite 34% having moderate-to-severe burden. What it means for HRT access.
Key Takeaways: A new Mayo Clinic Proceedings study (Kapoor et al., DOI: 10.1016/j.mayocp.2025.02.018) surveyed nearly 5,000 women aged 45-60 enrolled at four Mayo Clinic primary-care sites. More than 75% had menopause symptoms, 34% rated them moderate to very severe, sleep disturbances and weight gain each affected more than half of respondents, and approximately 87% never sought medical care. Only about 25% of symptomatic women had received any treatment. The dominant barriers: women normalize the symptoms, primary-care visits rarely surface menopause proactively, and residual fear from the 2002 WHI coverage still steers many women away from hormone therapy -- a fear the FDA's November 2025 black box removal has begun to address. The practical implication: most midlife women experiencing real, treatable menopause symptoms are not getting evaluated, and the modern HRT toolkit (transdermal estradiol, micronized progesterone, low-dose testosterone, plus the new neurokinin antagonists for women who cannot take hormones) is sitting on the shelf for the people it would help most.
What the Study Found
The cross-sectional analysis -- led by Dr. Ekta Kapoor, an endocrinologist and menopause specialist at Mayo Clinic Rochester, and published in Mayo Clinic Proceedings -- drew on the Mayo Clinic Hormones and ExpeRiences of Aging (HERA) registry. Of 32,469 women aged 45-60 invited from primary-care panels across four Mayo sites (Rochester, MN; Scottsdale, AZ; Jacksonville, FL; and Mayo Clinic Health System, Northwest Wisconsin), 4,914 completed the questionnaire -- a 15.1% response rate typical of mailed surveys in this population.
The headline numbers:
75%+ experienced menopause symptoms
34% rated symptoms moderate, severe, or very severe
>50% reported sleep disturbances and weight gain (each)
~87% did not seek medical care for their symptoms
~25% had received any treatment at the time of the survey
The reasons women gave for not seeking care clustered into three buckets: "I'm too busy," "I prefer to manage symptoms on my own," and "I didn't know there were effective treatments." A non-trivial subset also cited concerns about hormone therapy safety, residual from the 2002 Women's Health Initiative trial coverage.
These are not surprising answers in isolation. They are striking in aggregate because the study population was the most connected to primary care -- women enrolled in a registry at a tertiary academic medical center, with at least one continuous PCP relationship. If 87% of that population isn't seeking menopause care, the rate among women without continuous primary care -- the demographic majority -- is almost certainly higher.
Why This Is the Number That Matters
Strip the policy framing away and the practical implication is simple. Roughly one-third of midlife women are experiencing menopause symptoms severe enough to disrupt sleep, mood, work productivity, and quality of life. Effective evidence-backed treatment exists -- has existed for decades. The gap between "treatable symptoms" and "treated symptoms" is approximately 60 percentage points wide.
A few comparison points to calibrate:
For type 2 diabetes, the equivalent treatment gap is roughly 10-15% -- meaning ~85-90% of diagnosed diabetics are receiving some form of pharmacologic management.
For hypertension, roughly 70-75% of diagnosed patients are on at least one antihypertensive.
For erectile dysfunction in men, even with similar primary-care touchpoint constraints, treatment rates are estimated above 50%.
Menopause symptoms are the only major chronic symptom cluster in a developed-world adult population where the dominant treatment outcome is "do nothing." The reasons for that are partly cultural, partly historical (post-WHI), and partly structural (no dedicated specialty pipeline, inconsistent training in OB/GYN and primary care, fragmented insurance coverage).
The Three Barriers, Unpacked
1. Normalization
Hot flashes, sleep loss, weight gain, mood symptoms, joint pain, brain fog, low libido -- these are framed in popular culture and often by clinicians themselves as the natural cost of aging in a female body. They are not. They are the predictable consequence of declining estradiol, progesterone, and testosterone, and they are responsive to replacement of those hormones. The Mayo Clinic data shows that women internalize the cultural framing: "this is just menopause, I'll get through it." That sentence is the explanation for tens of millions of unmanaged symptom-years.
2. The Silent Primary-Care Visit
Most PCPs do not raise menopause proactively. The 15-minute visit slot is allocated to acute complaints and chronic disease management. Menopause symptoms -- which the patient may not even name as menopause -- often go unmentioned, and the patient leaves assuming her doctor would have brought it up if it mattered. The Mayo data captures this asymmetry: women in primary-care registries, with continuous access, simply weren't surfacing menopause to their physicians and their physicians weren't surfacing it to them.
3. The WHI Shadow
The 2002 Women's Health Initiative trial reported elevated breast cancer, stroke, and cardiovascular event rates in women on combined conjugated equine estrogens plus medroxyprogesterone acetate. Subsequent reanalysis showed the absolute risks were small, were largely driven by women initiating therapy more than 10 years after menopause, and did not extend to modern transdermal estradiol plus micronized progesterone. The reanalysis has been ongoing for 20 years. The headline ("HRT causes cancer") cemented itself in popular memory and has been remarkably difficult to dislodge.
In November 2025, the FDA -- after a comprehensive scientific review -- removed the boxed warnings from menopausal hormone therapy products, formally acknowledging that the WHI-era risk framing did not survive contact with the modern evidence base. That regulatory change is the most consequential menopause-care policy event in two decades. Whether it actually translates into the 87% number dropping over the next 3-5 years is the open question.
What "Care" Should Actually Look Like in 2026
The Mayo Clinic researchers did not just document the gap; they argued for proactive screening tools and structured patient-education interventions. A few of the components that the modern menopause-care standard now includes:
Women's HRT — Menopause-First Telehealth
Bioidentical estradiol, progesterone, and low-dose testosterone — all 50 states, unlimited physician access.
Proactive symptom screening. Standardized symptom questionnaires (the Menopause Rating Scale, the Greene Climacteric Scale) embedded into the annual PCP or OB/GYN visit. If the visit slot does not include it, the symptoms will not surface.
Tiered treatment matched to severity and contraindications. For most women with moderate-to-severe vasomotor symptoms and no absolute contraindications, the modern first-line regimen is transdermal estradiol 50-100 mcg/day plus oral micronized progesterone 100-200 mg at bedtime (for women with a uterus). Low-dose testosterone -- 5 mg/day cream or 0.25 mg/week injection -- layered on for residual energy, mood, and libido complaints once the estrogen-progesterone base is dialed in. For women who cannot take hormones (breast cancer history, VTE history, hormone-sensitive cancers), the neurokinin antagonists like elinzanetant and fezolinetant plus structured CBT for menopausal sleep and hot flash interference form the nonhormonal alternative.
Continuity and follow-up. A 3-month follow-up to titrate dosing, a 6-month check on labs and symptom response, an annual reassessment of risk-benefit. The chronic-disease-management cadence that diabetes and hypertension already get, applied to menopause.
Mental health and lifestyle integration. Sleep, mood, and metabolic symptoms often respond to the layered approach -- HRT plus CBT plus exercise plus targeted dietary intervention -- better than to any single component. The 2026 evidence base supports the combination; the current care delivery model under-delivers all of it.
Why Telehealth Is Closing the Gap
The structural barriers the Mayo study identifies -- not enough menopause specialists, primary care doesn't surface it, women are too busy for in-person visits -- map almost perfectly to what well-run women's HRT telehealth clinics now solve. A telehealth-first model offers:
Proactive intake screening. The first visit explicitly asks about hot flashes, sleep, mood, libido, energy, weight, joint pain, brain fog. Symptoms surface because the model is built to surface them.
Specialist-level prescribing without a wait list. The clinician is a menopause-trained NP or MD who prescribes the modern transdermal estradiol + progesterone + testosterone protocol as default, not as a niche request.
Mail-order pharmacy and continuous refills. The "too busy" barrier disappears when the medication ships to the door.
Async follow-up. Symptom titration happens by message, not by another 15-minute booked slot.
Transparent pricing. $100-200/month for the full hormone regimen, often less than the copay-and-pharmacy stack at a traditional clinic.
The trade-off is that telehealth platforms vary widely in protocol quality, transparency, and clinician training. Our best online HRT clinic for women breakdown grades platforms on diagnostic rigor, protocol depth, physician training, and pricing transparency. The short version: a few platforms are genuinely good, several are mediocre, and a few are direct-to-consumer marketing operations dressed up as clinics. The grading framework matters because the choice meaningfully affects symptom outcomes.
What the Data Doesn't Resolve
A few honest limitations of the Mayo Clinic study:
Single health-system population. All four sites are Mayo Clinic. Mayo patients tend to be more affluent, more insured, and more engaged with care than the national average. Whether the 87% number generalizes upward (most likely) or moves in other directions in different populations is unanswered.
15.1% response rate. Survey responders tend to be more engaged with their health than non-responders. The unsurveyed women may have even lower care-seeking rates.
2021 survey window. The questionnaire ran March-June 2021. The FDA black box removal happened in November 2025. The post-removal landscape may already be shifting, though the structural barriers (clinician training, insurance, access) move on a slower timeline than regulatory headlines.
Cross-sectional, not longitudinal. The data captures a snapshot, not a trajectory. We don't know from this study alone whether the 87% is improving year over year.
None of these undermines the central finding. They sharpen the question: the gap is at least 87 percentage points wide in the most-connected population, and the policy and care-delivery interventions required to close it are still in early innings.
What This Means for an Individual Woman
If you are 45-60 and experiencing menopause symptoms -- hot flashes, night sweats, sleep disruption, mood changes, weight gain, brain fog, low libido, joint pain -- the Mayo Clinic data is not abstract policy. It is a direct statement that roughly 9 in 10 women in your position have not sought care, and that the most likely reason is that no one prompted them to.
The practical sequence:
Surface the symptoms. Write them down. Rate severity 1-10. Note duration. This is the entry data for any clinician encounter.
Ask directly at your next primary-care or OB/GYN visit. "I think I'm in perimenopause / postmenopause. Can we discuss treatment options or refer to a menopause specialist?" If the answer is dismissive or vague, that is information.
Use the Menopause Society practitioner directory at menopause.org/find-a-menopause-practitioner to identify clinicians with formal menopause training (MSCP credential).
Consider a women's HRT telehealth platform as an alternative or supplement. The vetted-clinic comparison is at /clinics/best-online-hrt-clinic-women.
Bring the comparative-risk framing. Modern transdermal estradiol + micronized progesterone within 10 years of menopause has a favorable benefit-risk profile for most women. The 2002 WHI risk framing does not apply to this regimen in this window. The November 2025 FDA black box removal documents this.
The deeper point the Mayo data establishes: not seeking care is the default. Seeking care is the choice. The system has not been designed to surface the question for you, and the answers it would give if asked are now substantially better than what most women remember from a decade ago.
The Bottom Line
The Mayo Clinic Proceedings study (Kapoor et al., 2025) gives 2026 menopause care a single, hard-to-argue-with number: 87% of midlife women experiencing menopause symptoms do not seek medical care. That number is the largest measurable treatment gap for any major chronic symptom cluster in adult medicine. It is also the most actionable, because the treatments work, the safety evidence has improved, and the delivery model (telehealth-first, specialist-prescribed, integrated HRT plus testosterone plus nonhormonal options) is now mature enough to close the gap at scale.
The November 2025 FDA black box removal did the regulatory work. The infrastructure -- telehealth clinics, certified menopause practitioners, modern hormone formulations, neurokinin antagonists, integrated CBT -- is in place. The remaining variable is whether women experiencing symptoms surface them to a clinician who is equipped to act.
If you are in the 87%, the friction to leaving it is now lower than at any point in the past 20 years.
References
Kapoor E, et al. Addressing Menopause Symptoms: Barriers and Opportunities for Improvement. Mayo Clinic Proceedings. 2025. DOI: 10.1016/j.mayocp.2025.02.018.
U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. November 2025.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938.
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clin Proc. 2017;92(12):1842-1849.
What did the Mayo Clinic menopause study actually find?
Mayo Clinic Proceedings published a cross-sectional survey of nearly 5,000 women aged 45-60 enrolled in the HERA registry. More than 75% experienced menopause symptoms, 34% rated them moderate to very severe, sleep disturbances and weight gain were the most common complaints (each affecting more than half of respondents), and approximately 87% never sought medical care. The most-cited reasons were 'too busy,' 'preferred to manage on my own,' and 'unaware that effective treatments exist.' Only about 25% of symptomatic women had received any treatment at the time of the survey.
Why don't women seek care for menopause symptoms?
The study identified three dominant barriers. First, women normalize the symptoms -- they assume hot flashes, sleep loss, mood changes, and weight gain are inevitable and not treatable. Second, primary-care touchpoints rarely surface menopause proactively, so women conclude their doctor would have raised it if it mattered. Third, residual fear from the 2002 Women's Health Initiative coverage left a generation believing HRT causes breast cancer and heart attacks -- a belief the FDA's November 2025 black box removal has begun to reverse but has not yet erased. Add the structural barriers (no menopause specialist nearby, limited insurance coverage for compounded products, time off work for in-person visits) and the 87% number stops being surprising.
What symptoms were most common in the study?
Sleep disturbances and weight gain led the list, each reported by more than half of respondents. Hot flashes, night sweats, mood changes, brain fog, and joint pain followed. About 34% of the women rated their overall menopause symptoms as moderate, severe, or very severe -- meaning roughly one in three midlife women is experiencing genuinely disruptive symptoms that meet the clinical threshold for considering hormone therapy.
Is hormone therapy still considered safe for menopause symptoms?
For most women starting within 10 years of menopause onset and under age 60, yes. The FDA removed the black box warnings from menopausal hormone therapy products in November 2025 after a comprehensive review of the post-WHI evidence. Modern transdermal estradiol plus oral micronized progesterone (for women with a uterus) has a favorable benefit-risk profile in this window, reducing hot flashes by roughly 75%, protecting bone, and likely lowering cardiovascular and dementia risk. The risks the 2002 WHI flagged were largely driven by older oral conjugated estrogens plus medroxyprogesterone acetate in women initiating therapy more than a decade after menopause -- a different drug, route, and population than what most modern menopause clinics prescribe.
What can a woman do if she suspects she's perimenopausal but her doctor isn't engaging?
Three options, in order of friction. First, ask directly: 'I think I'm in perimenopause. Can we discuss hormone therapy or a referral to a menopause specialist?' Many primary care physicians follow patient cues. Second, find a Menopause Society-certified practitioner (MSCP) -- the directory at menopause.org is the cleanest filter for clinicians with formal menopause training. Third, use a women's-health telehealth clinic. Our writeup of the [best online HRT clinics for women](/clinics/best-online-hrt-clinic-women?from=menopause-care-barriers-mayo-clinic-study) covers the practical differences between platforms, what to expect from a first visit, and pricing for transdermal estradiol, progesterone, and low-dose testosterone.
Is the 87% number specific to Mayo Clinic patients or generalizable?
Mayo Clinic patients are arguably the most engaged primary-care population in the country -- they had a primary care physician, they were enrolled in a research registry, and they completed the survey. If 87% of that population didn't seek menopause care, the real-world number across women without continuous primary care is almost certainly higher. The Mayo number is the floor, not the ceiling.
Does testosterone play a role in menopause treatment too?
Yes, and it's frequently missed. Estradiol handles vasomotor symptoms (hot flashes, night sweats) and bone protection. Progesterone handles sleep onset and uterine protection. Low-dose testosterone -- typically 5 mg/day cream or 0.25 mg/week injection -- addresses the energy, mood, and libido symptoms that often persist after the estrogen layer is dialed in. The Mayo study did not specifically ask about testosterone use, but the prevalence of mood symptoms, fatigue, and low libido in the data is consistent with a layer of menopause-related androgen deficiency that the conventional estrogen-progesterone regimen does not address. See our [testosterone for menopause](/protocols/testosterone-for-menopause) writeup for protocol detail.
